Fabrizio et al. (2022) have shown that elevated levels of circulating RANKL are sufficient to cause skeletal muscle atrophy and bone resorption whereas anti-RANKL treatments improve muscle mass and function in cancer-associated cachexia (Pin et al., 2022). Here, TNFSF11 is linked to Cachexia.